Alnylam Pharmaceuticals (ALNY) Non Operating Income (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly Non Operating Income of -$47.0 million for Q1 2026, down 611.18% year-on-year from $9.2 million in Q1 2025, and up 74.87% on a QoQ basis from -$187.0 million in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of Non Operating Income data on file, last reported at -$47.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 611.18% year-over-year to -$47.0 million; the trailing twelve-month figure through Mar 2026 stood at -$327.3 million (down 93.75% YoY), and the FY2025 full-year result was -$178.4 million, up 11.01% from the prior year.
- Non Operating Income for Q1 2026 stood at -$47.0 million, up from -$187.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $9.2 million in Q1 2025 and bottomed at -$187.0 million in Q4 2025.
- The 5-year median for Non Operating Income is -$38.1 million (2022), against an average of -$51.1 million.
- The widest annual swing landed in 2023, when Non Operating Income sank 727.81%; it then soared 145.61% in 2025.
- A 5-year view of Non Operating Income shows it stood at -$2.6 million in 2022, then plunged by 727.81% to -$21.3 million in 2023, then tumbled by 317.23% to -$88.8 million in 2024, then slumped by 110.58% to -$187.0 million in 2025, then surged by 74.87% to -$47.0 million in 2026.
- The last three Non Operating Income figures came in at -$47.0 million (Q1 2026), -$187.0 million (Q4 2025), and -$74.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -8.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.98 Mn |
| Dec 31, 2025 | -186.99 Mn |
| Sep 30, 2025 | -74.15 Mn |
| Jun 30, 2025 | -19.16 Mn |
| Mar 31, 2025 | 9.19 Mn |
| Dec 31, 2024 | -88.80 Mn |
| Sep 30, 2024 | -29.53 Mn |
| Jun 30, 2024 | -59.78 Mn |
| Mar 31, 2024 | -20.15 Mn |
| Dec 31, 2023 | -21.28 Mn |
| Sep 30, 2023 | -57.66 Mn |
| Jun 30, 2023 | -35.42 Mn |
| Mar 31, 2023 | -22.56 Mn |
| Dec 31, 2022 | -2.57 Mn |
| Sep 30, 2022 | -38.05 Mn |
| Jun 30, 2022 | -82.99 Mn |
| Mar 31, 2022 | -92.62 Mn |
| Dec 31, 2021 | -65.74 Mn |
| Sep 30, 2021 | -22.56 Mn |
| Jun 30, 2021 | -42.17 Mn |
| Mar 31, 2021 | -13.02 Mn |
| Dec 31, 2020 | -10.14 Mn |
| Sep 30, 2020 | -594,000.00 |
| Jun 30, 2020 | 20.96 Mn |
| Mar 31, 2020 | 23.03 Mn |
| Dec 31, 2019 | 21.49 Mn |
| Sep 30, 2019 | 7.37 Mn |
| Jun 30, 2019 | 17.75 Mn |
| Mar 31, 2019 | 7.57 Mn |
| Dec 31, 2018 | 19.27 Mn |
| Sep 30, 2018 | 9.72 Mn |
| Jun 30, 2018 | 2.21 Mn |
| Mar 31, 2018 | 6.13 Mn |
| Dec 31, 2017 | 13.08 Mn |
| Sep 30, 2017 | -433,000.00 |
| Jun 30, 2017 | -523,000.00 |
| Mar 31, 2017 | -779,000.00 |
| Dec 31, 2016 | 300,000.00 |
| Sep 30, 2016 | 2.61 Mn |
| Jun 30, 2016 | 229,000.00 |
| Mar 31, 2016 | 5.24 Mn |
| Dec 31, 2015 | 175,000.00 |
| Sep 30, 2015 | -72,000.00 |
| Jun 30, 2015 | 1.59 Mn |
| Mar 31, 2015 | 1.01 Mn |
| Dec 31, 2014 | 4.01 Mn |
| Sep 30, 2014 | 524,000.00 |
| Jun 30, 2014 | 616,000.00 |
| Mar 31, 2014 | -82,000.00 |
| Dec 31, 2013 | -29,000.00 |
| Sep 30, 2013 | -12,000.00 |
| Jun 30, 2013 | 259,000.00 |
| Mar 31, 2013 | 5,000.00 |
| Dec 31, 2012 | 3.05 Mn |
| Sep 30, 2012 | -1.36 Mn |
| Jun 30, 2012 | -889,000.00 |
| Mar 31, 2012 | -475,000.00 |
| Dec 31, 2011 | -2.30 Mn |
| Sep 30, 2011 | -799,000.00 |
| Jun 30, 2011 | -16,000.00 |
| Mar 31, 2011 | 81,000.00 |
| Dec 31, 2010 | 1.93 Mn |
| Sep 30, 2010 | -604,000.00 |
| Jun 30, 2010 | -3.24 Mn |
| Mar 31, 2010 | -11,000.00 |
| Dec 31, 2009 | -161,000.00 |
| Sep 30, 2009 | -10,000.00 |
| Jun 30, 2009 | 618,000.00 |